Canadian Cancer Trials Group Bulletins

Trial Management Group

Trial Activation

We are very pleased to announce the activation of Canadian Cancer Trials Group/C17 SRC.6 (COG ARST1321) -- Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib.

This academic Intergroup trial is ground breaking for the adolescent and young adult community in North America. It has been jointly developed by the Children's Oncology Group (COG) and NRG Oncology. COG is the coordinating (lead) group and thus has primary responsibility for trial design, activation, data management, statistical analysis and publication. Within Canada, C17 and Canadian Cancer Trials Group have worked closely together to develop a harmonized process enabling accrual of pediatric and adult patients under one Clinical Trials Application and providing a unified approach to trial conduct.

It is hoped this will be the first of many trials crossing geographical and age boundaries.

Any centres interested in participating in this trial should contact Magda Monreal, Canadian Cancer Trials Group Study Coordinator, at